Intraocular Pressure Stratification & Glaucoma Risk
Categorises Goldmann applanation IOP (best of multiple readings, mid-morning) for ocular-hypertension and glaucoma decisions. Apply central corneal thickness (CCT) correction (Ehlers / Dresdner) where available — thin cornea (<540 µm) underestimates true IOP by ~2–5 mmHg.
Score interpretation
→ If glaucoma suspect (disc cupping, family history): repeat IOP, OCT-RNFL, visual fields, gonioscopy. Otherwise routine optometry interval.
→ Confirm with repeat readings + CCT. Per NICE NG81: no treatment if no other risk factors and CCT >555 µm; consider treatment in higher-risk patients (thin cornea, family history, Afro-Caribbean ethnicity).
→ Per NICE NG81 — offer 360° SLT first-line, alternative is topical PGA (latanoprost) target ≥20% reduction. Annual OCT + visual fields; treat to target IOP.
→ Same-day ophthalmology assessment (rule out acute angle closure, uveitic glaucoma, traumatic hyphaema with secondary rise, neovascular glaucoma). Initial topical β-blocker + α-agonist + topical/oral CAI ± osmotic agent (mannitol/glycerol) if angle closure. Definitive surgical / SLT plan once acute episode controlled.
Interpretation bands for the IOP Risk. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Selexipag · Pulmonary Arterial Hypertension
- Macitentan · Pulmonary Arterial Hypertension
- Retinol palmitate with white soft paraffin, light liquid paraffin, liquid paraffin and wool fat · Ocular lubricant ointment
- Yellow soft paraffin · Emollient / Ocular lubricant
- Propranolol (Portal Hypertension) · Antihypertensive
- Carvedilol (Portal Hypertension) · Non-Selective Beta-Blocker with Alpha₁-Blocking Activity
- Acute Red Eye / Vision Loss Screen · RCOphth 2020; NICE CKS
- Idiopathic Intracranial Hypertension · ABN; consensus 2018
- Acute Red Eye Assessment · RCOphth / AAO
- Acute Angle Closure Glaucoma · RCOphth / EGS Guidelines
- Retinal Detachment · RCOphth Guidelines / EURETINA
- Diabetic Retinopathy — Screening and Management · NICE NG28 2016 / NHS DES Programme
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.